Loading…
Employees: 1,403
Size Stratec (SBS.DE) is a Germany Health Care company (Medical Specialties) with a market value of $341M, the 197th largest of 205 Germany companies the cockpit tracks. Shares closed at €25.00 on 6 Nov 2026.
Performance Over six months the shares gained 40.6%, against -9.6% for the median peer and +2.6% for the Germany market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 3.0% over the last twelve months (peer median +7.6%); the operating margin is 2.6% (peer median 4.9%).
Valuation It trades at 16.4× forward earnings against a peer median of 15.3× (4th most expensive of 9).
Capital Return on invested capital runs 5.4 points below its cost of capital (6.8% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €245M | €251M | €258M | €270M | €275M |
| Revenue growth | — | -3% | -5% | -2% | — |
| Gross profit | €57.7M | €64.2M | €76.4M | €68.2M | €79.5M |
| EBITDA | €31.0M | €27.2M | €44.9M | €45.8M | €58.9M |
| Net income | -€395,000 | -€242,000 | €16.0M | €15.4M | €29.2M |
| Free cash flow | n/a | -€9.71M | €38.8M | €11.0M | -€18,000 |
| Capital expenditure | n/a | €16.2M | €18.2M | €17.3M | €19.0M |
| Total debt | €116M | €132M | €131M | €142M | €87.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SBS.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.6% | -5.6% | 3rd highest of 21 |
| 6-month return | +40.6% | -9.6% | 4th highest of 20 |
| Distance from 52-week high | -5.8% | -30.0% | highest of 21 |
| Revenue growth (TTM) | -3.0% | +7.6% | 6th lowest of 21 |
| Operating margin | 2.6% | 4.9% | 10th lowest of 21 |
| Forward P/E | 16.4× | 15.3× | 4th most expensive of 9 |
| ROIC minus cost of capital | -5.4 pp | -3.7 pp | 7th lowest of 18 |
| EV / EBITDA | 12.9× | 9.6× | 3rd most expensive of 11 |
| Net debt / EBITDA | 3.1× | -2.4× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 10.7× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | n/a | 26.0% | -11.9% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |